Mind Medicine (MindMed) (MNMD) is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the treatment of generalized anxiety disorder (GAD) and major depressive disorder (MDD).2024 Turns Out to Be a Transformational Year for MindMed2024 was a transformational year for the company when it executed many important milestones, one of which was initiating the 52-week Voyage phase III study on MM120 ODT in GAD ...